Test Price
2,800 AED✅ Home Collection Available
ARX Gene Mental Retardation, X‑Linked Type 29 Genetic Test in the UAE | 2800 AED | DHA Licensed
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO‑Certified Next‑Generation Sequencing (NGS) and clinically validated bioinformatics pipeline.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection (Available daily from 8 AM to 11 PM).
- Clinical Guidance: Telephonic Post‑Test Clinical Guidance with board‑certified genetic counsellors to interpret results in the context of the patient’s full clinical picture.
- Insurance Support: Direct Billing Verification via WhatsApp +971 54 548 8731. Our team handles pre‑approval with all major UAE insurers.
Test Overview & Methodology
This advanced NGS‑based test examines the entire coding region of the ARX gene, the major cause of X‑linked intellectual disability type 29 (XLID29). It identifies pathogenic variants linked to intellectual disability, epilepsy, movement disorders and brain malformations – enabling a definitive molecular diagnosis, carrier detection for female relatives and informed genetic counselling.
| Feature | Our ARX NGS Test | Closest Alternative (Microarray / Sanger) |
|---|---|---|
| Precision | Complete gene sequencing – detects point mutations, small indels, and splice variants with >99.9% analytical sensitivity | CMA misses intragenic point mutations; Sanger is limited to a few exons, often missing deep intronic variants |
| Methodology | NGS (Next‑Generation Sequencing) on Illumina platform with clinical‑grade bioinformatics | Chromosomal Microarray or single‑gene Sanger sequencing – lower resolution for gene‑specific mutations |
| Turnaround Time | 3 to 4 Weeks – backed by ISO‑certified Cold‑Chain logistics | Often 6–8 Weeks for comprehensive microarrays; bespoke Sanger panels can take longer |
| Price | 2800 AED – all‑inclusive, no hidden fees | 2500–4500 AED (variable, often excludes pre‑test genetic counselling) |
Physician Insight & Safety Protocols
“Every patient’s journey with intellectual disability is unique – this genetic test offers clarity but must be interpreted alongside a detailed neurological evaluation, family history and genetic counselling. I understand the emotional weight of such investigations and assure you we handle your child’s sample with the highest confidentiality and clinical rigour. A molecular diagnosis is the beginning of a personalised care plan, not an endpoint.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics (DHA Registration ID: 9294403)
Advisory Note
Do not discontinue any prescribed medication without consulting your treating physician. Anti‑epileptic or neurodevelopmental drugs should be managed only under specialist supervision.
Safety Exclusion Criteria & Emergency Red Flags
- Exclusion Criteria: Active febrile illness, uncontrolled seizure within 24 hours, or known severe bleeding disorder. For children unable to tolerate venipuncture, a dried blood spot (FTA card) collection can be arranged – please inform the phlebotomist in advance.
- Red Flags – seek immediate medical attention if: prolonged bleeding (>10 minutes), large haematoma, dizziness, or signs of infection (redness, warmth, pus) at the puncture site.
Patient FAQ & Clinical Guidance
1. What is the ARX Gene Mental Retardation, X‑Linked Type 29 Genetic Test?
This test uses next‑generation sequencing to detect mutations in the ARX gene responsible for X‑linked intellectual disability type 29, providing a molecular answer within 3–4 weeks. It covers all coding exons and flanking splice regions, delivering a definitive diagnosis when clinical suspicion is high – especially in boys with developmental delay, seizures or lissencephaly. The result empowers families with information about inheritance, prognosis and reproductive options.
2. Who should consider this test and how is it performed?
Any child or adult male with unexplained intellectual disability, early‑onset epilepsy, movement disorders such as dystonia, or brain imaging findings suggestive of lissencephaly should be offered ARX testing. Females with a family history of X‑linked intellectual disability may undergo carrier testing. The test requires a simple blood sample (1–2 mL in EDTA tube), extracted DNA or a dried blood spot on an FTA card; our certified phlebotomist performs the collection through the home‑collection service, strictly following cold‑chain protocols.
3. What do the results mean and what are the next steps?
A positive (pathogenic) result confirms the clinical diagnosis, clarifies prognosis, and enables cascade testing of at‑risk relatives. A negative result does not rule out other genetic causes; your neurologist may recommend broader gene panels or whole exome sequencing. All results are discussed in a dedicated post‑telehealth session with a clinical geneticist. Based on the result, early intervention (speech, physical therapy) and family planning can be optimised.
UAE Regulatory & Data Privacy Adherence
- All genetic testing is performed in accordance with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) – ensuring genetic data privacy and requiring informed consent.
- Testing for minors complies with Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields, requiring parental/guardian authorisation and mandatory genetic counselling.
- Clinical safety and patient consent are governed by Federal Decree‑Law No. 4 of 2016 on Medical Liability.
- ISO 9001:2015 Certified Facility – Cert: INT/EGQ/2509DA/3139; DHA Facility License: 1143.
- Clinical validity maintained through regular proficiency testing and adherence to CAP/CLIA‑equivalent standards.
Clinical & Logistical Metadata
| Test Name | ARX Gene Mental Retardation, X‑Linked Type 29 Genetic Test (NGS) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3 to 4 Weeks |
| Sample Type / Matrix | Peripheral Whole Blood (1–2 mL EDTA), Extracted DNA, or Dried Blood Spot (FTA Card) |
| Methodology Used | Next‑Generation Sequencing (NGS) – Illumina Platform with Clinical‑Grade Bioinformatics |
| ICD-10-CM Code | F78.9 (Intellectual Disability, Unspecified) |
| LOINC Code | 94221-1 (ARX gene mutation analysis in Blood or Tissue by Sequencing) |
| DHA Facility License & Address | License No. 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians